Showing results (41-50 of 155) with videos related to
Sort By:
Pageof 16
The Lancet. Oncology|February 19, 2010
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06)Joaquim Bellmunt, José Manuel Trigo, Emiliano Calvo, et al.Cancer Chemotherapy and Pharmacology|March 5, 2009
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancerJoaquim Bellmunt, Emiliano Calvo, Daniel Castellano, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 22, 2009
Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect studyAlejandro D Ricart, John Sarantopoulos, Emiliano Calvo, et al.Clinical and Translational Medicine|September 23, 2023
Uncovering therapeutic opportunities in the clinical development of antibody-drug conjugatesCristina Nieto-Jiménez, Adrián Sanvicente, Cristina Díaz-Tejeiro, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2020
Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT)Martin Smoragiewicz, Alex A Adjei, Emiliano Calvo, et al.Cancers|November 25, 2023
Patient Characteristics Associated with Growth of Patient-Derived Tumor Implants in Mice (Patient-Derived Xenografts)Tatiana Hernández Guerrero, Natalia Baños, Laura Del Puerto Nevado, et al.Targeted Oncology|June 15, 2014
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b studyIrene Brana, Antonio Calles, Patricia M LoRusso, et al.Journal for Immunotherapy of Cancer|August 4, 2025
Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trialEmiliano Calvo, Valentina Boni, Olivier Dumas, et al.Investigational New Drugs|December 20, 2022
A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumorsVictor Moreno, Ruth Perets, Tamar Peretz-Yablonski, et al.Clinical Colorectal Cancer|November 28, 2002
Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II studyEmiliano Calvo, Javier Cortés, Javier Rodríguez, et al.Pageof 16